ArticleBMC complementary medicine and therapies2026
Buddlejasaponin IV inhibits proliferation and migration via STAT3 suppression in gefitinib-resistant non-small cell lung cancer cells.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung cancer is a leading cause of death globally, with non-small-cell lung cancer (NSCLC) often developing resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs). This study explored the efficacy and mechanism of Buddlejasaponin IV (BJS IV) from Clinopodium chinense var. shibetchense in overcoming gefitinib resistance in NSCLC cells.
methodsCell proliferation was determined using the sulforhodamine B (SRB) assay. Mechanistic studies involved small interfering RNA (siRNA) and western blot analysis. Cell cycle and apoptosis were analyzed by flow cytometry. The impact of BJS IV on epithelial–mesenchymal transition (EMT) was evaluated through cell invasion and wound-healing assays. Angiogenesis was assessed via tube formation assay and real-time polymerase chain reaction (PCR). Drug combination efficacy was tested by the Chou–Talalay method.
resultsBJS IV inhibited proliferation in HCC827 and HCC827-gef cells with IC50 values of 4.50 µM and 7.84 µM, respectively. It suppressed activated signal transducer and activator of transcription (p-STAT3) in HCC827-gef cells, and STAT3 inhibition by siRNA restored gefitinib sensitivity. Long-term BJS IV exposure induced apoptosis by downregulating B-cell lymphoma-extra-large (Bcl-xL) and Bcl-2 and upregulating cleaved caspase 3, cleaved caspase 9 and cleaved poly (ADP-ribose) polymerase (PARP) in HCC827-gef cells. BJS IV also inhibited migration and invasion by downregulating EMT markers N-cadherin, snail, and vimentin. It significantly suppressed vascular endothelial growth factor (VEGF) expression in HCC827-gef cells, inhibiting angiogenesis in VEGF-induced tube formation in HUVECs. Combined BJS IV and gefitinib treatment showed synergistic antiproliferative effects in HCC827-gef cells.
conclusionsBJS IV demonstrated potential antiproliferative activity via STAT3 suppression and apoptosis induction. BJS IV also inhibited migration, invasion, EMT transition, and angiogenesis in HCC827-gef cells, suggesting BJS IV as a potential therapeutic agent for overcoming gefitinib resistance in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.